The silyl phosphine compound of the present invention is represented by the formula (1) and has an arsenic content of not more than 1 ppm. The process for producing a silyl phosphine compound of the present invention is a process comprising mixing a basic compound, a silylating agent and phosphine to obtain a solution containing a silyl phosphine compound, removing a solvent from the solution to obtain a concentrated solution of a silyl phosphine compound, and distilling the concentrated solution, wherein an arsenic content in the phosphine is adjusted to not more than 1 ppm by volume in terms of arsine. The process for producing InP quantum dots of the present invention uses, as a phosphorus source, a silyl phosphine compound represented by the formula (1) and having an arsenic content of not more than 1 ppm by mass. ##STR00001## (For definition of R, see the specification.)

The silyl phosphine compound of the present invention is represented by the formula (1) and has an arsenic content of not more than 1 ppm. The process for producing a silyl phosphine compound of the present invention is a process comprising mixing a basic compound, a silylating agent and phosphine to obtain a solution containing a silyl phosphine compound, removing a solvent from the solution to obtain a concentrated solution of a silyl phosphine compound, and distilling the concentrated solution, wherein an arsenic content in the phosphine is adjusted to not more than 1 ppm by volume in terms of arsine. The process for producing InP quantum dots of the present invention uses, as a phosphorus source, a silyl phosphine compound represented by the formula (1) and having an arsenic content of not more than 1 ppm by mass. ##STR00001## (For definition of R, see the specification.)

This invention provides for prodrug Compounds I, pharmaceutical compositions thereof, and their use in treating HIV infection.

##STR00001## wherein: X is C or N with the proviso that when X is N, R.sup.1 does not exist; W is C or N with the proviso that when W is N, R.sup.2 does not exist; V is C; E is hydrogen or a pharmaceutically acceptable salt thereof; and Y is selected from the group consisting of

##STR00002##

Also, this invention provides for intermediate Compounds II useful in making prodrug Compounds I.

##STR00003## wherein: L and M are independently selected from the group consisting of C.sub.1-C.sub.6 alkyl, phenyl, benzyl, trialkylsilyl, -2,2,2-trichloroethoxy and 2-trimethylsilylethoxy.

An electrolyte solution for a lithium secondary battery includes an organic solvent, a lithium salt, and a fluorine-based additive in which a terminal difluoro-phosphite group (—OPF.sub.2) is bonded to a branched saturated hydrocarbon group. The fluorine-based additive prevent side reactions in the electrolyte solution to improve stability of a cathode active material.

An electrolyte solution for a lithium secondary battery includes an organic solvent, a lithium salt, and a fluorine-based additive in which a terminal difluoro-phosphite group (—OPF.sub.2) is bonded to a branched saturated hydrocarbon group. The fluorine-based additive prevent side reactions in the electrolyte solution to improve stability of a cathode active material.

The present invention relates to a method for producing an InP-based quantum dot precursor from a phosphorus source and an indium source, in which a silylphosphine compound represented by the following Formula (1) with a content of a compound represented by the following Formula (2) of 0.3 mol % or less is used as the phosphorus source. Further, the present invention provides a method for producing an InP-based quantum dot comprising heating an InP quantum dot precursor to a temperature of 200° C. or more and 350° C. or less to obtain an InP quantum dot. ##STR00001##
(R is as defined in the specification.)

The present invention relates to a method for producing an InP-based quantum dot precursor from a phosphorus source and an indium source, in which a silylphosphine compound represented by the following Formula (1) with a content of a compound represented by the following Formula (2) of 0.3 mol % or less is used as the phosphorus source. Further, the present invention provides a method for producing an InP-based quantum dot comprising heating an InP quantum dot precursor to a temperature of 200° C. or more and 350° C. or less to obtain an InP quantum dot. ##STR00001##
(R is as defined in the specification.)

Disclosed are an electrolyte for a lithium secondary battery and a lithium secondary battery comprising the same. The electrolyte for a lithium secondary battery, according to an embodiment, can comprise: a nonaqueous organic solvent; a lithium salt; a first additive comprising a compound represented by a specific chemical formula; and a second additive including at least one of lithium difluorophosphate (LiPO.sub.2F.sub.2), a cyclic carbonate including a fluorine atom, and a dinitrile compound.

Disclosed are an electrolyte for a lithium secondary battery and a lithium secondary battery comprising the same. The electrolyte for a lithium secondary battery, according to an embodiment, can comprise: a nonaqueous organic solvent; a lithium salt; a first additive comprising a compound represented by a specific chemical formula; and a second additive including at least one of lithium difluorophosphate (LiPO.sub.2F.sub.2), a cyclic carbonate including a fluorine atom, and a dinitrile compound.

Described are improved linking agents that are useful for facilitating the attachment of targeting groups, pharmacokinetic (PK) enhancers or modifiers, or other delivery agents to oligonucleotides. The described linking agents may exhibit improved reaction yields, stability, and biological activity, particularly when used in connection with oligonucleotide-based compounds, such as RNA interference (RNAi) agents.